TrialSignal
Clinical trial intelligence report
Phase I, Single-center, Randomized, Double-blind, Single-dose, Parallel Comparison of Pharmacokinetic and Safety Similarities Between Meperizumab Injection and NUCALA® in Healthy Male Volunteers
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT05353179
Status
UNKNOWN
Phase
Phase I
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Executive brief
Investment-Ready Snapshot
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is conducting a Phase I clinical trial to evaluate the pharmacokinetics and safety of Meperizumab injection compared to NUCALA® in healthy male volunteers. The study aims to enroll 88 subjects and assess the similarity in drug behavior and safety profiles.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05353179
Indication
Granulomatosis With Polyangiitis
Modality
monoclonal antibody
Target
Meperizumab injection (humanized monoclonal antibody targeting IL-5 receptor)
Intervention
Meperizumab injection, NUCALA®
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.